Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344147 | 0.94 | OPRK1 (0.32) | KDM5AGOT1OPRK1 | |
| SCHEMBL1171264 | 0.77 | ALDH1A1 (0.41) | OPRK1 | |
| SCHEMBL17675448 | 0.74 | CYP11B2 (0.42) | KDM5AGOT1OPRK1 | |
| SCHEMBL7353417 | 0.73 | — | — | |
| SCHEMBL29765569 | 0.73 | — | — | |
| SCHEMBL16060787 | 0.73 | — | — | |
| SCHEMBL277675 | 0.72 | CYP11B2 (0.46) | KDM5AOPRK1 | |
| SCHEMBL31119419 | 0.72 | CYP11B2 (0.46) | KDM5AOPRK1 | |
| SCHEMBL449107 | 0.72 | ALDH1A1 (0.44) | — | |
| SCHEMBL2102983 | 0.71 | KDM5A (0.34) | KDM5AGOT1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389527-B2 | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | claimed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | claimed |
| EP-2240488-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009100375-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | claimed |
| US-8389527-B2 | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2240488-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009100375-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP4K2, MAP3K15 | KDM5A 764/4885GOT1 1231/4885OPRK1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.